Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738699 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
A Phase 2 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 2
- Development phase
- 415
- Enrollment target
NCT00738699: Clinical Trial Phase 2 study, sponsored by Morphotek.
NCT00738699 is a Phase 2 study that was terminated before completion, run by Morphotek. The registered enrollment target is 415 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (212% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00738699, a Phase 2 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 415 participants
- Enrollment target
Study Summary
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
Primary Outcome
PFS was defined as the time (in months) from the date of randomization to the date of the first observation of progression as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST), or death regardless of cause. If progression or death was not observed, the PFS time was censored at the date of the last tumor assessment without evidence of progression before the date of initiation of further antitumor treatment, or the cutoff date (whichever was earlier).
Interventions
- DRUG Paclitaxel
- DRUG 0.9% Saline
- DRUG MORAb-003 (farletuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Why NCT00738699 stopped before completion
NCT00738699 is an interventional study that assigns participants to a tested intervention. The registered 415 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (212% higher).
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT00738699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00738699 about?
NCT00738699 is a clinical study titled "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer". The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
What is the current status of trial NCT00738699?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 415 participants. The study started on 2008-09. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00738699?
The interventions under investigation include: Paclitaxel (DRUG), 0.9% Saline (DRUG), MORAb-003 (farletuzumab) (DRUG).
Who is sponsoring clinical trial NCT00738699?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00738699's enrollment target sits among peer trials
415 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- NCT05520099 · 416 participants
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia